Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of BR2251 in primary gout with hyperuricemia
CTR20261050Phase 2Active
- Sponsor
- Bozhirui Biopharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BR2251 in idiopathic gout, hyperuricemia, sponsored by Bozhirui Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
BR2251
03
Conditions
idiopathic gouthyperuricemia
Beyond the preview
Go deeper on CTR20261050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261050.